

Supplementary Table 1. Characteristics of 495 cases by immunosuppressant type at the time of iMN diagnosis in total population

Characteristic	Cyclophosphamide	Cyclosporine	Tacrolimus	Mycophenolate mofetil	Rituximab
No. of patients	182	158	51	44	16
Male sex	105 (57.7)	95 (60.1)	27 (52.9)	29 (65.9)	10 (62.5)
Age (yr)*	58.9 ± 11.9	53.5 ± 14.3	55.2 ± 11.6	53.3 ± 13.0	53.6 ± 14.3
Body mass index (kg/m ²)	25.0 ± 3.0	25.1 ± 3.6	25.8 ± 3.4	26.0 ± 3.5	28.2 ± 7.4
Systolic BP (mmHg)	125.7 ± 17.3	125.6 ± 16.7	122.7 ± 16.5	126.6 ± 14.5	122.8 ± 16.4
Diastolic BP (mmHg)	74.4 ± 11.3	74.5 ± 11.2	73.2 ± 11.4	76.4 ± 10.5	71.6 ± 10.4
Comorbid conditions					
Hypertension	93 (51.1)	61 (23.6)	30 (58.8)	19 (43.2)	7 (43.8)
Diabetes	28 (15.4)	20 (12.7)	7 (13.7)	5 (11.4)	4 (25.0)
Coronary heart disease	6 (3.3)	7 (4.4)	2 (3.9)	1 (2.3)	2 (12.5)
Cerebrovascular disease*	14 (7.7)	5 (3.2)	2 (3.9)	0 (0)	0 (0)
Hemoglobin (g/dL)	13.0 ± 2.0	13.6 ± 1.8	13.3 ± 1.7	13.0 ± 2.3	14.1 ± 1.7
Total protein (g/dL)	4.9 ± 0.8	5.1 ± 1.0	5.2 ± 0.9	5.2 ± 1.0	4.7 ± 0.6
Albumin (g/dL)	2.5 ± 0.6	2.6 ± 0.7	2.6 ± 0.6	2.5 ± 0.7	2.3 ± 0.5
Blood urea nitrogen (mg/dL)	16.4 ± 8.9	15.5 ± 7.2	15.9 ± 6.1	16.8 ± 11.1	17.6 ± 9.3
Serum creatinine (mg/dL)	1.0 ± 0.7	0.9 ± 0.5	0.9 ± 0.4	1.1 ± 0.6	1.1 ± 0.6
eGFR (mL/min/1.73 m ²)*	82.9 ± 26.6	91.8 ± 24.7	86.7 ± 23.4	84.4 ± 28.4	84.0 ± 34.6
Total cholesterol (mg/dL)	296.1 ± 105.0	303.5 ± 104.7	262.4 ± 92.0	289.4 ± 98.9	308.9 ± 106.2
LDL cholesterol (mg/dL)	179.6 ± 81.1	192.7 ± 83.3	175.5 ± 68.7	217.3 ± 82.4	144.8 ± 10.6
Uric acid (mg/dL)	6.3 ± 1.8	6.1 ± 1.9	6.4 ± 1.8	6.5 ± 2.2	6.4 ± 1.1
Urine PCR (g/g)	7.45 ± 4.9	6.3 ± 4.7	6.8 ± 4.7	6.4 ± 4.2	7.4 ± 5.1
≥3.5	112 (61.5)	89 (56.3)	36 (70.6)	25 (56.8)	11 (68.8)

Data are expressed as number (%) or mean ± standard deviation.

BP, blood pressure; eGFR, estimated glomerular filtration rate; iMN, idiopathic membranous nephropathy; LDL, low-density lipoprotein; PCR, protein-creatinine ratio.

*p < 0.05 among five immunosuppressive agent groups.